STOCK TITAN

Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Turning Point Therapeutics (NASDAQ: TPTX) announced that President and CEO Athena Countouriotis will participate in a fireside chat at the 42nd Annual Cowen Healthcare Conference. The session is scheduled for March 8, 2022, from 11:10 a.m. to 11:40 a.m. ET, accessible via webcast on their investor page. The company focuses on precision oncology, developing therapies targeting genetic drivers of cancer, with key candidates including repotrectinib for non-small cell lung cancer and several others in its pipeline.

Positive
  • None.
Negative
  • None.

SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a fireside chat at the 42nd Annual Cowen Healthcare Conference.

Dr. Countouriotis’ session is scheduled to take place on Tuesday, March 8 from 11:10 a.m. to 11:40 a.m. ET. The session will be accessible via webcast through the Investors page of www.tptherapeutics.com.

About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.

Contact:
Adam Levy
ir@tptherapeutics.com
858-867-6366


FAQ

When is the Turning Point Therapeutics fireside chat scheduled?

The Turning Point Therapeutics fireside chat is scheduled for March 8, 2022, from 11:10 a.m. to 11:40 a.m. ET.

Who will represent Turning Point Therapeutics at the Cowen Healthcare Conference?

President and CEO Athena Countouriotis will represent Turning Point Therapeutics at the Cowen Healthcare Conference.

How can I access the webcast for the fireside chat?

The webcast for the fireside chat can be accessed through the Investors page on the Turning Point Therapeutics website.

What is the lead drug candidate of Turning Point Therapeutics?

The lead drug candidate of Turning Point Therapeutics is repotrectinib, targeting genetic drivers of non-small cell lung cancer.

What other drug candidates are in Turning Point Therapeutics' pipeline?

Turning Point Therapeutics' pipeline includes elzovantinib, TPX-0046, and TPX-0131, targeting various oncogenic drivers.

TPTX

NASDAQ:TPTX

TPTX Rankings

TPTX Latest News

TPTX Stock Data

3.81B
49.72M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link